ObRb downregulation increases breast cancer cell sensitivity to tamoxifen. (Q53555843)

15 May 2018

title

ObRb downregulation increases breast cancer cell sensitivity to tamoxifen. (English)

1 reference

15 May 2018

1 reference

Yingying Qian

1

1 reference

15 May 2018

Dongmin Shi

2

1 reference

15 May 2018

Jinrong Qiu

3

1 reference

15 May 2018

Fang Zhu

4

1 reference

15 May 2018

Jing Qian

5

1 reference

15 May 2018

Shaohua He

6

1 reference

15 May 2018

Yongqian Shu

7

1 reference

15 May 2018

Yongmei Yin

8

1 reference

15 May 2018

Xiaofeng Chen

9

1 reference

15 May 2018

publication date

7 April 2015

1 reference

15 May 2018

published in

Tumor Biology

1 reference

15 May 2018

volume

36

1 reference

15 May 2018

page(s)

6813-6821

1 reference

15 May 2018

issue

9

1 reference

15 May 2018

https://scigraph.springernature.com/pub.10.1007/s13277-015-3375-5

exact match

0 references

cites work

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3375-5

Rational management of endocrine resistance in breast cancer: a comprehensive review of estrogen receptor biology, treatment options, and future directions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3375-5

Adjuvant endocrine treatment of early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3375-5

Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3375-5

Leptin: a multifunctional hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3375-5

Obesity, adipocytokines, and insulin resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3375-5

The ins and outs of leptin receptor activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3375-5

Divergent signaling capacities of the long and short isoforms of the leptin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3375-5

Increased expression of leptin and the leptin receptor as a marker of breast cancer progression: possible role of obesity-related stimuli.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3375-5

Enhanced expression of leptin and leptin receptor (OB-R) in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3375-5

Leptin induces a proliferative response in breast cancer cells but not in normal breast cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3375-5

Leptin attenuates the anti-estrogen effect of tamoxifen in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3375-5

Leptin receptor signal transduction: OBRa and OBRb of fa type

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3375-5

Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3375-5

The multifactorial role of leptin in driving the breast cancer microenvironment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3375-5

Leptin as a potential target for estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3375-5

Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3375-5

Evidence that leptin through STAT and CREB signaling enhances cyclin D1 expression and promotes human endometrial cancer proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3375-5

A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3375-5

Long-term treatment with tamoxifen facilitates translocation of estrogen receptor alpha out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3375-5

leptin-induced growth stimulation of breast cancer cells involves recruitment of histone acetyltransferases and mediator complex to CYCLIN D1 promoter via activation of Stat3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3375-5

A cell-type-specific transcriptional network required for estrogen regulation of cyclin D1 and cell cycle progression in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3375-5

Expression of estrogen receptor alpha increases leptin-induced STAT3 activity in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3375-5

Leptin Enhances, via AP-1, Expression of Aromatase in the MCF-7 Cell Line

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3375-5

High expression of leptin receptor mRNA in breast cancer tissue predicts poor prognosis for patients with high, but not low, serum leptin levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3375-5

Cellular and molecular crosstalk between leptin receptor and estrogen receptor-{alpha} in breast cancer: molecular basis for a novel therapeutic setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3375-5

Constitutive overexpression of cyclin D1 but not cyclin E confers acute resistance to antiestrogens in T-47D breast cancer cells

21 January 2018

1 reference

12 December 2020

Leptin promotes the proliferation and migration of human breast cancer through the extracellular-signal regulated kinase pathway.

1 reference

12 December 2020

Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer

1 reference

12 December 2020

Tamoxifen adjuvant treatment duration in early breast cancer: initial results of a randomized study comparing short-term treatment with long-term treatment. Fédération Nationale des Centres de Lutte Contre le Cancer Breast Group

1 reference

12 December 2020

Tamoxifen metabolism and its effect on endocrine treatment of breast cancer.

1 reference

12 December 2020

10.1007/S13277-015-3375-5

Identifiers

DOI

1 reference

15 May 2018

PubMed ID

25846733

1 reference

15 May 2018